NCT02243618View on ClinicalTrials.gov

The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer

NACompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

January 14, 2015

Primary Completion Date

April 14, 2016

Study Completion Date

April 14, 2016

Conditions
Gastric AdenomaEarly Gastric Cancer
Interventions
DRUG

Polaprezinc

Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.

DRUG

Rebamipide

Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.

Trial Locations (1)

120-752

Sevrance hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02243618 - The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer | Biotech Hunter | Biotech Hunter